References analysis of the Wikipedia article "达格列净" in the Chinese version

doi.org (Global: 2^nd place; Chinese: 23^rd place)

The EMPA-KIDNEY Collaborative Group; Herrington, William G.; Staplin, Natalie; Wanner, Christoph; Green, Jennifer B.; Hauske, Sibylle J.; Emberson, Jonathan R.; Preiss, David; Judge, Parminder; Mayne, Kaitlin J.; Ng, Sarah Y. A. Empagliflozin in Patients with Chronic Kidney Disease. The New England Journal of Medicine. 2023-01-12, 388 (2) [2025-10-28]. ISSN 1533-4406. PMC 7614055 

. PMID 36331190. doi:10.1056/NEJMoa2204233.

Heerspink, Hiddo J. L.; Stefánsson, Bergur V.; Correa-Rotter, Ricardo; Chertow, Glenn M.; Greene, Tom; Hou, Fan-Fan; Mann, Johannes F. E.; McMurray, John J. V.; Lindberg, Magnus; Rossing, Peter; Sjöström, C. David. Dapagliflozin in Patients with Chronic Kidney Disease. The New England Journal of Medicine. 2020-10-08, 383 (15) [2025-10-28]. ISSN 1533-4406. PMID 32970396. doi:10.1056/NEJMoa2024816.

Perkovic, Vlado; Jardine, Meg J.; Neal, Bruce; Bompoint, Severine; Heerspink, Hiddo J. L.; Charytan, David M.; Edwards, Robert; Agarwal, Rajiv; Bakris, George; Bull, Scott; Cannon, Christopher P. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. The New England Journal of Medicine. 2019-06-13, 380 (24) [2025-10-28]. ISSN 1533-4406. PMID 30990260. doi:10.1056/NEJMoa1811744.

Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet (London, England). 2022-11-19, 400 (10365) [2025-10-28]. ISSN 1474-547X. PMC 7613836 

. PMID 36351458. doi:10.1016/S0140-6736(22)02074-8.

McDonagh, Theresa A.; Metra, Marco; Adamo, Marianna; Gardner, Roy S.; Baumbach, Andreas; Böhm, Michael; Burri, Haran; Butler, Javed; Čelutkienė, Jelena; Chioncel, Ovidiu; Cleland, John G. F. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021-09-21, 42 (36) [2025-10-28]. ISSN 1522-9645. PMID 34447992. doi:10.1093/eurheartj/ehab368.

Heidenreich, Paul A.; Bozkurt, Biykem; Aguilar, David; Allen, Larry A.; Byun, Joni J.; Colvin, Monica M.; Deswal, Anita; Drazner, Mark H.; Dunlay, Shannon M.; Evers, Linda R.; Fang, James C. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2022-05-03, 79 (17) [2025-10-28]. ISSN 1558-3597. PMID 35379504. doi:10.1016/j.jacc.2021.12.011.

McMurray, John J. V.; Solomon, Scott D.; Inzucchi, Silvio E.; Køber, Lars; Kosiborod, Mikhail N.; Martinez, Felipe A.; Ponikowski, Piotr; Sabatine, Marc S.; Anand, Inder S.; Bělohlávek, Jan; Böhm, Michael. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. The New England Journal of Medicine. 2019-11-21, 381 (21) [2025-10-28]. ISSN 1533-4406. PMID 31535829. doi:10.1056/NEJMoa1911303.

Nassif, Michael E.; Windsor, Sheryl L.; Tang, Fengming; Khariton, Yevgeniy; Husain, Mansoor; Inzucchi, Silvio E.; McGuire, Darren K.; Pitt, Bertram; Scirica, Benjamin M.; Austin, Bethany; Drazner, Mark H. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. Circulation. 2019-10-29, 140 (18) [2025-10-28]. ISSN 1524-4539. PMID 31524498. doi:10.1161/CIRCULATIONAHA.119.042929.

Ali, Ahmed E.; Mazroua, Muhammad Sabry; ElSaban, Mariam; Najam, Nadia; Kothari, Aditi S.; Mansoor, Taha; Amal, Tanya; Lee, Joanna; Kashyap, Rahul. Effect of Dapagliflozin in Patients with Heart Failure: A Systematic Review and Meta-Analysis. Global Heart. 2023, 18 (1) [2025-10-28]. ISSN 2211-8179. PMC 10453961 

. PMID 37636033. doi:10.5334/gh.1258.

Wiviott, Stephen D.; Raz, Itamar; Bonaca, Marc P.; Mosenzon, Ofri; Kato, Eri T.; Cahn, Avivit; Silverman, Michael G.; Zelniker, Thomas A.; Kuder, Julia F.; Murphy, Sabina A.; Bhatt, Deepak L. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. The New England Journal of Medicine. 2019-01-24, 380 (4) [2025-10-28]. ISSN 1533-4406. PMID 30415602. doi:10.1056/NEJMoa1812389.

Zinman, Bernard; Wanner, Christoph; Lachin, John M.; Fitchett, David; Bluhmki, Erich; Hantel, Stefan; Mattheus, Michaela; Devins, Theresa; Johansen, Odd Erik; Woerle, Hans J.; Broedl, Uli C. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. The New England Journal of Medicine. 2015-11-26, 373 (22) [2025-10-28]. ISSN 1533-4406. PMID 26378978. doi:10.1056/NEJMoa1504720.

Packer, Milton; Anker, Stefan D.; Butler, Javed; Filippatos, Gerasimos; Pocock, Stuart J.; Carson, Peter; Januzzi, James; Verma, Subodh; Tsutsui, Hiroyuki; Brueckmann, Martina; Jamal, Waheed. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. The New England Journal of Medicine. 2020-10-08, 383 (15) [2025-10-28]. ISSN 1533-4406. PMID 32865377. doi:10.1056/NEJMoa2022190.

Cox, Zachary L.; Collins, Sean P.; Hernandez, Gabriel A.; McRae, A. Thomas; Davidson, Beth T.; Adams, Kirkwood; Aaron, Mark; Cunningham, Luke; Jenkins, Cathy A.; Lindsell, Christopher J.; Harrell, Frank E. Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure. Journal of the American College of Cardiology. 2024-04-09, 83 (14) [2025-10-28]. ISSN 1558-3597. PMID 38569758. doi:10.1016/j.jacc.2024.02.009.

McGuire, Darren K.; Shih, Weichung J.; Cosentino, Francesco; Charbonnel, Bernard; Cherney, David Z. I.; Dagogo-Jack, Samuel; Pratley, Richard; Greenberg, Michelle; Wang, Shuai; Huyck, Susan; Gantz, Ira. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. JAMA cardiology. 2021-02-01, 6 (2) [2025-10-28]. ISSN 2380-6591. PMC 7542529 

. PMID 33031522. doi:10.1001/jamacardio.2020.4511.

Bhattarai, Mukul; Salih, Mohsin; Regmi, Manjari; Al-Akchar, Mohammad; Deshpande, Radhika; Niaz, Zurain; Kulkarni, Abhishek; Siddique, Momin; Hegde, Shruti. Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis. JAMA network open. 2022-01-04, 5 (1) [2025-10-28]. ISSN 2574-3805. PMC 8733833 

. PMID 34985519. doi:10.1001/jamanetworkopen.2021.42078.

Zannad, Faiez; Ferreira, João Pedro; Pocock, Stuart J.; Anker, Stefan D.; Butler, Javed; Filippatos, Gerasimos; Brueckmann, Martina; Ofstad, Anne Pernille; Pfarr, Egon; Jamal, Waheed; Packer, Milton. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet (London, England). 2020-09-19, 396 (10254) [2025-10-28]. ISSN 1474-547X. PMID 32877652. doi:10.1016/S0140-6736(20)31824-9.

di Mauro, Gabriella; Mascolo, Annamaria; Gaio, Mario; Rafaniello, Concetta; De Angelis, Antonella; Berrino, Liberato; Paolisso, Giuseppe; Rossi, Francesco; Capuano, Annalisa. The Reporting Frequency of Ketoacidosis Events with Dapagliflozin from the European Spontaneous Reporting System: The DAPA-KETO Study. Pharmaceuticals (Basel, Switzerland). 2022-02-25, 15 (3) [2025-10-28]. ISSN 1424-8247. PMC 8952809 

. PMID 35337085. doi:10.3390/ph15030286.

Cherney, David Z. I.; Dekkers, Claire C. J.; Barbour, Sean J.; Cattran, Daniel; Abdul Gafor, Abdul Halim; Greasley, Peter J.; Laverman, Gozewijn D.; Lim, Soo Kun; Di Tanna, Gian Luca; Reich, Heather N.; Vervloet, Marc G. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. The Lancet. Diabetes & Endocrinology. 2020-07, 8 (7) [2025-10-28]. ISSN 2213-8595. PMID 32559474. doi:10.1016/S2213-8587(20)30162-5.

Yau, Kevin; Dharia, Atit; Alrowiyti, Ibrahim; Cherney, David Z. I. Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations. Kidney International Reports. 2022-07, 7 (7) [2025-10-28]. ISSN 2468-0249. PMC 9263228 

. PMID 35812300. doi:10.1016/j.ekir.2022.04.094.

nih.gov (Global: 4^th place; Chinese: 5^th place)

ncbi.nlm.nih.gov

. PMID 36331190. doi:10.1056/NEJMoa2204233.

. PMID 36351458. doi:10.1016/S0140-6736(22)02074-8.

. PMID 37636033. doi:10.5334/gh.1258.

. PMID 33031522. doi:10.1001/jamacardio.2020.4511.

. PMID 34985519. doi:10.1001/jamanetworkopen.2021.42078.

. PMID 35337085. doi:10.3390/ph15030286.

. PMID 35812300. doi:10.1016/j.ekir.2022.04.094.

pubmed.ncbi.nlm.nih.gov

. PMID 36331190. doi:10.1056/NEJMoa2204233.

. PMID 36351458. doi:10.1016/S0140-6736(22)02074-8.

. PMID 37636033. doi:10.5334/gh.1258.

. PMID 33031522. doi:10.1001/jamacardio.2020.4511.

pmc.ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

Farxiga- dapagliflozin tablet, film coated. DailyMed. National Institutes of Health, National Library of Medicine, U.S. Department of Health & Human Services. 3 February 2020 [5 May 2020]. （原始内容存档于30 October 2020）.

worldcat.org (Global: 5^th place; Chinese: 12^th place)

. PMID 36331190. doi:10.1056/NEJMoa2204233.

. PMID 36351458. doi:10.1016/S0140-6736(22)02074-8.

. PMID 37636033. doi:10.5334/gh.1258.

. PMID 33031522. doi:10.1001/jamacardio.2020.4511.

. PMID 34985519. doi:10.1001/jamanetworkopen.2021.42078.

. PMID 35337085. doi:10.3390/ph15030286.

. PMID 35812300. doi:10.1016/j.ekir.2022.04.094.

达格列净 (Chinese Wikipedia)

cfda.gov.cn (Global: low place; Chinese: low place)

samr.cfda.gov.cn

doi.org (Global: 2^nd place; Chinese: 23^rd place)

drugs.com (Global: 399^th place; Chinese: 208^th place)

europa.eu (Global: 68^th place; Chinese: 209^th place)

ema.europa.eu

fda.gov (Global: 447^th place; Chinese: 581^st place)

gov.uk (Global: 432^nd place; Chinese: 770^th place)

nih.gov (Global: 4^th place; Chinese: 5^th place)

ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

web.archive.org (Global: 1^st place; Chinese: 1^st place)

worldcat.org (Global: 5^th place; Chinese: 12^th place)

达格列净 (Chinese Wikipedia)

cfda.gov.cn (Global: low place; Chinese: low place)

samr.cfda.gov.cn

doi.org (Global: 2nd place; Chinese: 23rd place)

drugs.com (Global: 399th place; Chinese: 208th place)

europa.eu (Global: 68th place; Chinese: 209th place)

ema.europa.eu

fda.gov (Global: 447th place; Chinese: 581st place)

gov.uk (Global: 432nd place; Chinese: 770th place)

nih.gov (Global: 4th place; Chinese: 5th place)

ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

web.archive.org (Global: 1st place; Chinese: 1st place)

worldcat.org (Global: 5th place; Chinese: 12th place)

doi.org (Global: 2^nd place; Chinese: 23^rd place)

drugs.com (Global: 399^th place; Chinese: 208^th place)

europa.eu (Global: 68^th place; Chinese: 209^th place)

fda.gov (Global: 447^th place; Chinese: 581^st place)

gov.uk (Global: 432^nd place; Chinese: 770^th place)

nih.gov (Global: 4^th place; Chinese: 5^th place)

web.archive.org (Global: 1^st place; Chinese: 1^st place)

worldcat.org (Global: 5^th place; Chinese: 12^th place)